AMRN News 1.37 05/16/2014 04:26:25 Amarin Corporation Plc (A

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amarin Corporation Plc (AMRN) 1.37 $AMRN

Why Amarin (AMRN) Stock Is Plummeting Today
at The Street - Thu May 15, 1:37PM CDT
Amarin (AMRN) is down big after announcing private exchange transaction of outstanding senior notes.

Why Amarin Corporation PLC Shares Tumbled
Sean Williams, The Motley Fool - Motley Fool - Thu May 15, 12:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Amarin , a biopharmaceutical company...

Amarin Down 8.6%, Shares Slide into the Red (AMRN)
Comtex SmarTrend(R) - Thu May 15, 10:09AM CDT
Amarin (NASDAQ:AMRN) is one of today's worst performing low-priced stocks, down 8.6% to $1.39 on 1.4x average daily volume. Thus far today, Amarin has traded 2.4 million shares, vs. average volume of 1.7 million shares per day. The stock has underperformed the Dow (-8.6% to the Dow's -0.9%) and underperformed the S&P 500 (-8.6% to the S&P's -1.0%) during today's trading.

Amarin Announces Private Exchange Transactions Regarding Outstanding Senior Exchangeable Notes
GlobeNewswire - Thu May 15, 5:19AM CDT
Amarin Corporation plc (Nasdaq:AMRN) ("Amarin", announced today that it and its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the "Issuer", have entered into separate, privately negotiated exchange agreements with certain holders of its outstanding 3.50% Exchangeable Senior Notes due 2032 issued on January 9, 2012 (the "2012 Notes" pursuant to which the Issuer will exchange $118.734 million in aggregate principal amount of the 2012 Notes for $118.734 million in aggregate principal amount of new 3.50% May 2014 Exchangeable Senior Notes due 2032 (the "2014 Notes". Following the closing of these transactions, $31.266 million in aggregate principal amount of the 2012 Notes will remain outstanding with terms unchanged. The 2014 Notes will be exchangeable into American Depositary Shares of Amarin ("ADSs" at the option of the holders at an initial exchange rate of 384.6154 ADSs per $1,000 principal amount of 2014 Notes (equivalent to an initial exchange price of approximately $2.60 per ADS), subject to adjustment in certain circumstances. The exchange is expected to close on May 20, 2014, subject to customary closing conditions.

Downgrade Alert for Amarin (AMRN)
Comtex SmarTrend(R) - Mon May 12, 7:11AM CDT
Amarin (NASDAQ:AMRN) was downgraded from Buy to Neutral at Citigroup today. The stock closed yesterday at $1.51 on volume of 2.4 million shares, above average daily volume of 1.8 million. Amarin Corporation PLC is a clinical-stage biopharmaceutical company. The Company researches, develops, and commercializes drugs for the treatment of hypertriglyceridemia, central nervous system disorders, and cardiovascular diseases.

Health Care Stocks to Watch Today: Amarin Corporation plc, Jazz Pharmaceuticals, and Vanda Pharmaceu
George Budwell, The Motley Fool - Motley Fool - Fri May 09, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Amarin ,  Jazz Pharmaceuticals and  Vanda Pharmaceuticals .   Amarin reports first-quarter earnings The much-maligned biotech Amarin reported...

Amarin Reports First Quarter 2014 Financial Results and Provides Update on Operations
GlobeNewswire - Fri May 09, 6:01AM CDT
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended March 31, 2014, and provided an update on company operations.

Amarin to Report First Quarter 2014 Results and Host Conference Call on May 9, 2014
GlobeNewswire - Mon May 05, 8:41AM CDT
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2014 financial results and provide an operational update on Friday, May 9, at 8:00 a.m. ET. The conference call will follow the anticipated release of the company's first quarter 2014 financial results earlier that day.

Amarin Announces Presentation of New MARINE and ANCHOR Post-Hoc Analyses at National Lipid Association Annual Scientific Sessions Showing Vascepa(R) Significantly Reduced Apolipoprotein C-III Levels
GlobeNewswire - Fri May 02, 7:01AM CDT
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the presentation at the National Lipid Association Annual Scientific Sessions, of new post-hoc analyses of the MARINE and ANCHOR studies that showed the use of Vascepa (icosapent ethyl) capsules significantly reduced apolipoprotein C-III (ApoC-III) levels. ApoC-III is a small protein that resides on various lipoproteins, and is an important regulator of lipoprotein and triglyceride (TG) metabolism. This research is being presented today by Christie M. Ballantyne, M.D. from Baylor College of Medicine as part of a peer-reviewed poster session at the National Lipid Association Annual Scientific Sessions in Orlando, Florida.

Technical Roundup on Health Care Stocks -- Research on Amarin, United Therapeutics, Hologic, and NxStage Medical
PR Newswire - Fri Apr 25, 1:10PM CDT
On Thursday, April 24, 2014, the NASDAQ Composite ended at 4,148.34, up 0.52%, the Dow Jones Industrial Average finished the day flat at 16,501.65, and the S&P 500 closed at 1,878.61, up 0.17%. The gains were narrow based as four out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.80, down 0.20%, while the index has advanced 0.39% in the last one month. Investor-Edge has initiated coverage on the following equities: Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR), Hologic Inc. (NASDAQ: HOLX) and NxStage Medical Inc. (NASDAQ: NXTM). Free technical research on AMRN, UTHR, HOLX and NXTM can be downloaded upon signing up at:

The Supreme Court Will Decide the Fate of a Blockbuster
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Apr 14, 5:30PM CDT
Recently, Teva Pharmaceuticals lost a patent lawsuit over its multiple sclerosis drug Copaxone, which makes up a crucial 40% of the company's income. However, the U.S. Supreme Court has announced that it will hear Teva's appeal of this Appeals...

Amarin Corp. and Kowa Pharmaceuticals to Begin Joint Vascepa Promotion in May
ACCESSWIRE - Fri Apr 11, 11:25AM CDT
Amarin Corp. PLC (NASDAQ:AMRN) stock volume was tepid Apr. 10, with just 1,595,690 shares, a third of its three-month average volume of 4,405,235 shares.

More Trouble Looming for Amarin Corporation?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 09, 1:30PM CDT
Amarin Corp. can't seem to catch a break these days. Almost immediately after inking a co-promotional deal for the company's lone commercial product, Vascepa, with Kowa Pharmaceuticals America, Teva Pharmaceuticals announced yesterday they are...

Partner Signed! Is Amarin's Turnaround Beginning?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun Apr 06, 11:12AM CDT
Amarin has announced news long awaited by investors -- a partnership with a big pharma. Although the pharma itself is not a household name, Japan's Kowa Pharmaceuticals will essentially triple the sales force for Vascepa. Sales of the...

Can This Drive Growth for Amarin Corporation plc?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Apr 01, 1:30PM CDT
Small-cap biopharmaceutical Amarin has made it clear that the company is not giving up on Vascepa without a fight, several of them actually. In addition to challenging the FDA's decisions to rescind a Special Protocol Assessment (SPA) on the...

Amarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa(R) (icosapent ethyl) Capsules
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Amarin Corporation plc (Nasdaq:AMRN) and Kowa Pharmaceuticals America, Inc., two biopharmaceutical companies focused on the development and commercialization of therapeutics to improve cardiovascular health, today announced an agreement to co-promote Amarin's flagship product, Vascepa (icosapent ethyl) capsules, in the United States. Vascepa is approved for use in the United States as an adjunct to diet to reduce triglyceride levels in adult patients with severe (greater-than or equal to 500 mg/dL) hypertriglyceridemia. In bringing together two companies focused on the primary care and cardiovascular health communities, the agreement is designed to benefit a greater number of patients.

Biotech Equities Technical Study -- Research on Prana Biotechnology, Amarin, United Therapeutic, and OPKO Health
PR Newswire - Fri Mar 28, 11:19AM CDT
On Thursday, March 27, 2014, the NASDAQ Composite ended at 4,151.23, down 0.54%, the Dow Jones Industrial Average edged 0.03% lower to 16,264.23, and the S&P 500 closed at 1,849.04, down 0.19%. The losses were broad based with seven out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 671.20, down 0.13%, and the index has fallen by 2.20% in last one month. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR) and OPKO Health Inc. (NYSE: OPK). Free technical research on PRAN, AMRN, UTHR and OPK can be downloaded upon signing up at:

Amarin Corporation plc. Analyst Report: Special Situation \ Turnaround Opportunity in Biopharmaceuticals - Targeting large existing cardiovascular health market by BrokerBank Securities, Inc.
PR Newswire - Fri Mar 28, 6:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN), an established biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health is in the process of attempting a turnaround to return to a growth trajectory. The Company's lead product, Vascepa (icosapent ethyl) capsules, is approved by the U.S. FDA for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Mar 28, 5:00AM CDT
Keep these under-$10 biotech stocks on your radar.

Better Chance of Making a Comeback: Amarin plc or VIVUS, Inc.?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 1:30PM CDT
I am a strong advocate of investing in so-called "comeback stories." My belief is underscored by the notable comebacks of Best Buy  and Netflix  in recent times. Within a few short months , Best Buy gained more than 200% and Netflix did even...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 173

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Fall Pest Risks Linger as Mild Weather Extends Threat

Updated Category News Views 0

A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...

Continue Reading
Volta M100 Puts Flexibility at Pad Printing's Center

Updated Category News Views 43

A tabletop printer rarely earns a second glance, but the Volta M100 is making a sensible argument: small manufacturers do not need another rigid box that becomes obsolete the minute a job changes. Boston Industrial Solutions has introduced the Volta M100 as a pad-printing machine built around adjustability, operator convenience, and software that can be upgraded as...

Continue Reading
Broadridge Brings Boyman In to Sharpen Its Market Story

Updated Category News Views 44

Financial plumbing rarely gets applause, which is precisely why Broadridge needs somebody who can explain its value without turning the pitch into alphabet soup. Lauren Boyman arrives as chief marketing and communications officer on November 23, taking charge of global marketing, corporate communications, product positioning, digital strategy, lead generation and thought...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 44

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
UN Integrity Accelerator Targets Corporate Corruption

Updated Category News Views 84

Corruption rarely arrives wearing a villain costume; it shows up as a rushed payment, a friendly intermediary, or a contract nobody wants examined too closely. That is why the United Nations Global Compact's new Business Integrity Accelerator deserves a sober look. Launched November 18, 2026, the programme is not a magic shield, and nobody should sell it as one. But it...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 0

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 178

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 0

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 26

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Crypto Volatility and the REX Osprey XRP ETF

Updated Category News Views 134

Cryptocurrency Market Overview and Recent Trends Up until October, the cryptocurrency market was experiencing significant growth, with a total capitalization reaching approximately $4.28 trillion. This surge was driven by abundant liquidity and a heightened risk appetite among investors. However, the capital markets can be unpredictable, leading to a swift and adverse...

Continue Reading
Intelligent Bio Inks Global Deal to Expand Drug Testing Solutions

Updated Category News Views 126

Intelligent Bio Solutions Launches Global Distribution Pact Intelligent Bio Solutions Inc. (NASDAQ: INBS) has recently announced an exciting global distribution partnership with SMARTOX. This collaboration aims to introduce their innovative SmarTest Patch, a cutting-edge product designed for drug detection, to international markets beyond the U.S. and Canada, marking a...

Continue Reading
Discover the Long-Term Growth of American Financial Group AFG Stock

Updated Category News Views 148

The Remarkable Journey of American Financial Group (AFG) American Financial Group (AFG) has significantly outperformed the market over the past twenty years, showing an annualized return of 9.37%, which surpasses the market by 1.29%. With a market capitalization standing at an impressive $10.39 billion, AFG is a noteworthy player in the financial sector. Investment...

Continue Reading
Current Sentiment Analysis: Canaan Inc's Short Interest Insights

Updated Category News Views 352

Canaan Inc's Current Short Interest Overview Canaan Inc (NYSE: CAN) is witnessing changes in its stock sentiment, particularly regarding its short interest. Recent reports indicate that the short interest, expressed as a percentage of the float, has dropped by 8.14%. Currently, 36.17 million shares are sold short, representing 8.58% of the total shares available for...

Continue Reading
CalExitNow Push for CA GOP Ban & Sovereignty Talks

Updated Category News Views 296

California's Political Pot Stirs In the wild world of politics, California stands as a fiery beacon yet again. This time, CalExitNow, a fiery group championing California's self-determination, is taking aim at the state’s Republican Party. Reminds me of a stock under pressure—hesitate at your peril as the winds of change sweep through. Disqualification Petition: A...

Continue Reading